Eucrates Biomedical Acquisition Corp.

Eucrates Biomedical Acquisition Corp. operates as a blank Check company focusing on acquiring, engaging in a share exchange, share reconstruction and amalgamations. The company was founded by Stelios Papadopoulos, Parag Saxena, Evangelos Vergetis and Daphne Karydas on August 21, 2020 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Company anticipates that it will not be able to consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association.

Eucrates Biomedical Acquisition Corp. Announces Liquidation

News for Eucrates Biomedical Acquisition Corp. Stock (EUCR)